As of May 12, 2026
We will taken on the challenge of “drug discovery innovation” to create new value by combining drug discovery technologies and disease research.
And also, we will expand target modalities and disease fields and pursue in-licensing initiatives in a wide range of areas to broaden our development pipeline, and proactive partnering activities.
Ph3 ～ Application submitted※ Updated (As of Feb 4, 2026)
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| PhⅢ (Sep 2022) |
KRP-R120 / Interstitial lung disease: ILD (pulmonary sarcoidosis) |
aTyr pharma | It is a fusion protein drug having the action to suppress, by binding to neuropilin-2 (NRP2) receptor, the excessive activation of immune cells, and is a potential first-in-class therapy to treat inflammatory diseases such as pulmonary sarcoidosis. |
| PhⅢ※(May 2026) | KRP-114VP / Overactive bladder |
Merck | Additional Indication for Beova in pediatric patients. |
DTx※ Updated (As of Feb 4, 2026)
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| SUSMED | KRP-DT123 | Tinnitus | Collaboration research and sales agreement for development of Digital Therapeutics (DTx) in otolaryngology Field (Nov 2022) Confirmatory study initiated (May 2026)※ |
| Hyfe | KRP-DC125 | Chronic Cough | Development and commercialization agreement for DTx for chronic cough. Confirmatory study in preparation |
POC Project (PhⅠ ～ PhⅡ)
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| PhⅠ Bayer |
KRP-S124 (BAY2925976) / OSA |
Bayer | BAY2925976 works as an ADRA2C antagonist, helping to centrally reduce upper airway collapse. It is expected to improve the temporary apneas and hypopneas commonly observed in patients with OSA. License agreement to obtained the exclusive worldwide rights to manufacture, develop, and commercialize BAY2925976 and its backup compound.(Dec 2024) |
| PhⅠ※ Hinge Bio, Inc. |
KRP-A225 (HB2198) / Systemic Lupus Erythematosus (SLE) etc. |
Hinge Bio, Inc. | A bispecific antibody targeting CD19 and CD20 on the surface of B cells. Expected to provide therapeutic benefit for SLE by "reset” the immune system through B cell depletion. Enter into a Collaboration and License Agreement ofHB2198 in Japan for SLE and other diseases (September 2025) |
| PhⅠ Biodol |
KRP-126※(BDT272) / Neuropathic Pain |
Biodol Therapeutics | BDT272 is anticipated to demonstrate effective analgesic properties by negatively modulating FLT3, a receptor tyrosine kinase implicated in the pathogenesis and maintenance of chronic pain condition such as neuropathic pain. Exercised the option rights and acquired the rights for development, manufacturing, and commercialization in Japan, South Korea, and Taiwan. (Mar 2026) Phase 1 trial in preparation (Japan) |
Licensing development (License-out)
| Stage/Overseas | Compound / Code | Licensee | Origin | Features |
|---|---|---|---|---|
| preclinical | KRP-M223 | Novartis | In-house | MRGPRX2 antagonist. |
Option Agreement
| Stage | Code / Target | Origin | Features |
|---|---|---|---|
| PhⅡ Cyrano |
CYR-064 / Post viral loss of smell |
Cyrano | CYR-064, phosphodiesterase inhibitor (PDEi) theophylline, targets the inhibition of cAMP degradation thereby increasing intracellular concentrations and increasing olfactory neuron excitability. |